Bismuth subcitrate as treatment of diarrhea in fragile patients with SARS-CoV-2 infection

Sopena, Eugenia; Canadell, Laura; Qanneta, Rami

doi:10.1016/j.medcle.2022.10.002

array:24 ["pii" => "S2387020622004867" "issn" => "23870206" "doi" => "10.1016/j.medcle.2022.10.002" "estado" => "S300" "fechaPublicacion" => "2022-11-11" "aid" => "6060" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2022" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2022;159:453-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0025775322004225" "issn" => "00257753" "doi" => "10.1016/j.medcli.2022.07.017" "estado" => "S300" "fechaPublicacion" => "2022-11-11" "aid" => "6060" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2022;159:453-4" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "Carta científica" "titulo" => "Subcitrato de bismuto en el tratamiento de la diarrea en pacientes frágiles con infección por SARS-CoV-2" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "453" "paginaFinal" => "454" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Bismuth subcitrate as treatment of diarrhea in fragile patients with SARS-CoV-2 infection" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Eugenia Sopena, Laura Canadell, Rami Qanneta" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Eugenia" "apellidos" => "Sopena" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Canadell" ] 2 => array:2 [ "nombre" => "Rami" "apellidos" => "Qanneta" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020622004867" "doi" => "10.1016/j.medcle.2022.10.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020622004867?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775322004225?idApp=UINPBA00004N" "url" => "/00257753/0000015900000009/v1_202210270533/S0025775322004225/v1_202210270533/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S238702062200482X" "issn" => "23870206" "doi" => "10.1016/j.medcle.2022.05.020" "estado" => "S300" "fechaPublicacion" => "2022-11-11" "aid" => "6023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Med Clin. 2022;159:e59-e60" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "SMARCA4-deficient undifferentiated tumor: A case report" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "e59" "paginaFinal" => "e60" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tumor indiferenciado deficiente en SMARCA4: descripción de un caso" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1170 "Ancho" => 904 "Tamanyo" => 437812 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0095" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "A) H&E; 30×. Carcinoma-like areas with eosinophilic cytoplasm and nuclei with moderate atypia (red arrow) along with sarcomatoid areas with rhabdoid cells and moderate atypia (black asterisk). Frequent patterns of mitosis in both components. B) Immunohistochemistry showing loss of SMARCA4. Tumor cells do not stain compared to lymphocytes, which are positive, and can be used as an internal control." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marta Segado Martínez, Gema Ruiz García" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Marta" "apellidos" => "Segado Martínez" ] 1 => array:2 [ "nombre" => "Gema" "apellidos" => "Ruiz García" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775322003669" "doi" => "10.1016/j.medcli.2022.05.017" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775322003669?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S238702062200482X?idApp=UINPBA00004N" "url" => "/23870206/0000015900000009/v1_202211040711/S238702062200482X/v1_202211040711/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S2387020622004909" "issn" => "23870206" "doi" => "10.1016/j.medcle.2022.05.021" "estado" => "S300" "fechaPublicacion" => "2022-11-11" "aid" => "6011" "copyright" => "Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Med Clin. 2022;159:447-52" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "Special article" "titulo" => "Anaemia and acute coronary syndrome: A complex clinical scenario" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "447" "paginaFinal" => "452" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Anaemia y síndrome coronario agudo: Un escenario clínico complejo" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1612 "Ancho" => 2925 "Tamanyo" => 251100 ] ] "descripcion" => array:1 [ "en" => "Hypotheses explaining why red blood cell transfusion (RBCT) might not improve outcomes. 2,3-DPG: 2,3-diphosphoglycerate; ADP: adenosine diphosphate; NO: nitric oxide." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Marc Izquierdo-Ribas, Pedro Cepas-Guillén, Eduardo Flores-Umanzor, Rut Andrea" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Marc" "apellidos" => "Izquierdo-Ribas" ] 1 => array:2 [ "nombre" => "Pedro" "apellidos" => "Cepas-Guillén" ] 2 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Flores-Umanzor" ] 3 => array:2 [ "nombre" => "Rut" "apellidos" => "Andrea" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020622004909?idApp=UINPBA00004N" "url" => "/23870206/0000015900000009/v1_202211040711/S2387020622004909/v1_202211040711/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Bismuth subcitrate as treatment of diarrhea in fragile patients with SARS-CoV-2 infection" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "453" "paginaFinal" => "454" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Eugenia Sopena, Laura Canadell, Rami Qanneta" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Eugenia" "apellidos" => "Sopena" "email" => array:1 [ 0 => "essopena.gipss@gencat.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Canadell" ] 2 => array:2 [ "nombre" => "Rami" "apellidos" => "Qanneta" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Hospital Sociosanitario Francolí, Tarragona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Subcitrato de bismuto en el tratamiento de la diarrea en pacientes frágiles con infección por SARS-CoV-2" ] ] "textoCompleto" => "On 12 March 2020, the World Health Organisation declared that the world was experiencing a pandemic due to human-to-human respiratory transmission of the new ®-coronavirus SARS-CoV-2. While many people with coronavirus disease 2019 (COVID-19) present with respiratory symptoms, a variable but significant percentage, ranging from 34% to 60% of patients with COVID-19 infection, present with gastrointestinal symptoms such as anorexia, vomiting, diarrhoea and abdominal pain<a class="elsevierStyleCrossRef" href="#bib0005">1</a> that are not always associated with respiratory symptoms or symptoms. In fact, viruses have been found in the stool of patients with COVID-19<a class="elsevierStyleCrossRef" href="#bib0010">2</a> and diarrhoea has been reported in up to 34% of cases.<a class="elsevierStyleCrossRef" href="#bib0015">3</a> The mechanism of diarrhoea in COVID-19 patients involves the interaction between the viral spike (S) protein with angiotensin-converting enzyme 2 (ACE2) and the TMPRSS2 protease. Both enzymes are not only present in the respiratory tract, but also, to a lesser extent, in the epithelium of the small intestine.<a class="elsevierStyleCrossRef" href="#bib0020">4</a>Bismuth colloidal compounds such as bismuth subsalicylate are antidiarrhoeal drugs with a dual antisecretory and antimicrobial mechanism of action: on the one hand, it stimulates the absorption of fluids and electrolytes through the intestinal wall by inhibiting chloride secretion, and on the other hand, when hydrolysed to salicylic acid, it inhibits the synthesis of prostaglandins responsible for intestinal inflammation and hypermotility. They also have antimicrobial effects as they bind to the enterotoxins of some bacteria such as E. coli, through their conversion to bismuth oxychloride and bismuth hydroxide. Clinical guidelines specify that bismuth subsalicylate is indicated for the treatment of moderate diarrhoea and common digestive complaints such as heartburn and is now also indicated as an adjuvant in the treatment of Helicobacter pylori.According to utilitarian ethics, in the context of the SARS-CoV-2 pandemic, a prioritisation of the use of health resources is established. This implies that frail, chronically ill elderly patients, who are also often institutionalised in social or residential care facilities with a high incidence of COVID-19, do not have access to mechanical ventilation and therefore have even higher mortality. Diarrhoea is a major problem in these patients, so we designed a prospective study in which the main objective was to determine the efficacy of treatment with bismuth subcitrate (the colloidal bismuth compound available in Spain) in frail patients who are not candidates for mechanical ventilation and admission to the ICU or referral to an acute hospital, with COVID-19 infection and acute diarrhoea as the main or relevant symptom.To be included in the study, SARS-CoV-2 infection had to be diagnosed by RT-PCR and be a geriatric patient with frailty criteria. Patients with a formal contraindication for treatment with colloidal bismuth compounds, such as the presence of previous kidney failure, bleeding ulcers, hemophilia, or hypersensitivity to salicylates, were excluded.In this prospective, open-label, single-arm study, all enrolled patients were treated with colloidal bismuth subcitrate (trade name in Spain: Gastrodenol®) from the day they had more than two clearly liquid stools or a total number of stools per day greater than 3 between liquid and pasty. The dosage administered was Gastrodenol® 240 mg (2 tablets) given every 12 h, half an hour before breakfast and dinner on an empty stomach. The study protocol called for treatment to be completed 48 h after cessation of diarrhoea. The endpoint of the study was the number of diarrhoeal stools per day and the number of days with diarrhoeal stools since the day of starting treatment. The study was approved by the CREC of the participating center and by the Spanish Agency for Medicines and Medical Devices in April 2020, under its COVID-19 study incentive programme.A total of 21 patients (10 women) were included between April 2020 and July 2021, in different waves or peaks of the pandemic. The first 8 were included during the beginning of the pandemic, or what would later be known as the first wave, between March and May 2020. The median age was 78 years (62–92), with a median Charlson index of 4 (1–7). The median number of stools per day at inclusion was 4 stools, with a minimum of 2 and a maximum of 30 stools. Six patients (29%) had 6 or more stools/day. Eight patients (38%) had a fever of more than 38° C. From the date of initiation of bismuth subcitrate treatment until complete disappearance of diarrhoea (more than 24 h without diarrhoeal stools), a median of 4 days elapsed (1–16), with the 2 patients with the highest number of stools, 30 and 15 stools/day, showing resolution of diarrhoea in 2 and 5 days, respectively. Only in 5 patients (24%) the duration was longer than 6 days. A stool culture and Clostridium difficile toxin was requested in all cases, with negative results, thus ruling out a cause of diarrhoea other than COVID-19. In the last 2 cases included, corresponding to the fifth wave, the onset of diarrhoea was the prodrome of the clinical and respiratory worsening of the patient. The percentage of deaths during admission was 24%, with no relation to age (Mann-Whitney U test P = .60), duration of diarrhoea (P = .20) or Charlson index (P = .313). Patients who did not die had a higher mean number of stools than those who died, with a trend close to statistical significance (6.63 vs. 3.00; P = .075). The only side effect observed was the presence of black discolouration in the stool during treatment.In conclusion, colloidal bismuth subcitrate treatment was effective in resolving diarrhoea in frail patients with COVID-19 infection, especially in those patients with a high amount of stools/day.Ethical considerationsThe study has been approved by the CREC of the Institut d'Investigacions Sanitàries Pere Virgili (IISPV) in Tarragona and by the Spanish Medicines Agency (AEMPS). Patients verbally consented to inclusion in the study, and this was recorded in the medical records. The CREC granted the exemption from signed written consent, given the COVID-19 pandemic situation, as was customary at the time.FundingThe study has not required funding.Conflict of interestsThe authors declare that they have no conflicts of interest concerning this study." "textoCompletoSecciones" => array:1 [ "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Ethical considerations" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Funding" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Conflict of interests" ] 3 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 pandemic: pathophysiology and manifestations from the gastrointestinal tract" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Galanopoulos" 1 => "F. Gkeros" 2 => "A. Doukatas" 3 => "G. Karianakis" 4 => "C. Pontas" 5 => "N. Tsoukalas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3748/wjg.v26.i31.4579" "Revista" => array:6 [ "tituloSerie" => "World J Gastroenterol." "fecha" => "2020" "volumen" => "26" "paginaInicial" => "4579" "paginaFinal" => "4588" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32884218" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong Cohort: systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.S. Cheung" 1 => "I.F.N. Hung" 2 => "P.P.Y. Chan" 3 => "K.C. Lung" 4 => "E. Tso" 5 => "R. Liu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2020.03.065" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology." "fecha" => "2020" "volumen" => "159" "paginaInicial" => "81" "paginaFinal" => "95" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32251668" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "X. Li" 1 => "S. Xu" 2 => "M. Yu" 3 => "K. Wang" 4 => "Y. Tao" 5 => "Y. Zhou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaci.2020.04.006" "Revista" => array:6 [ "tituloSerie" => "J Allergy Clin Immunol." "fecha" => "2020" "volumen" => "146" "paginaInicial" => "110" "paginaFinal" => "118" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32294485" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "44]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. D’Amico" 1 => "D.C. Baumgart" 2 => "S. Danese" 3 => "L. Peyrin-Biroulet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cgh.2020.04.001" "Revista" => array:6 [ "tituloSerie" => "Clin Gastroenterol Hepatol." "fecha" => "2020" "volumen" => "18" "paginaInicial" => "1663" "paginaFinal" => "1672" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32278065" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000015900000009/v1_202211040711/S2387020622004867/v1_202211040711/en/main.assets" "Apartado" => array:4 [ "identificador" => "43311" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000015900000009/v1_202211040711/S2387020622004867/v1_202211040711/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020622004867?idApp=UINPBA00004N"]

ISSN: 2387-0206

Launched in 1943, Medicina Clínica is a fortnightly journal aimed at the promotion of clinical research and practice among internal medicine and other specialists. The key characteristics of Medicina Clínica are the scientific and methodological rigor of its manuscripts, the topicality of its contents, and, especially, its practical focus with highly useful information for clinical practice. Medicina Clínica is predominantly interested in publishing original research manuscripts, which are rigorously selected according to their quality, originality, and interest, and also in continued medical education-oriented manuscripts, which are commissioned by the journal to relevant authors (Editorials, Reviews, and Diagnosis and Treatment). These manuscripts contain updated topics with a major clinical or conceptual relevance in modern medicine. The journal adheres to the standards of academic research publications in all aspects including peer-review and ethical principles. Medicina Clínica is included in the General and Internal Medicine category of Thomson Reuters.

See more Open Access Option

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, SciVerse ScienceDirect

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.371

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.511

View more metrics

Journal Information

Previous article | Next article

Vol. 159. Issue 9.

Pages 453-454 (November 2022)

Lee este artículo en Español

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Medicina Clínica (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publish in

Medicina Clínica

Tools

Free access articles

Associations of physical activity, sedentary time,...

Med Clin. 2024;163:327-35

Burden of COVID-19 variant omicron in immunocompromised...

Med Clin. 2024;163:347-59

Raynaud phenomenon in a baseball...

Med Clin. 2024;163:e79

Medicina Clínica (English Edition) follows the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter